Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data

被引：0
作者：
Ani John
Baiyu Yang
Roma Shah
机构：
[1] Roche Diagnostics,
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Adherence; Biomarker; First-line treatment; Guidelines; Non-small cell lung cancer; Precision medicine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1552 / 1566
页数：14
相关论文
共 50 条
  • [41] Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study
    Li, Hongxin
    Zhao, Wen
    Chang, Caiyun
    Xuan, Tiantian
    Wang, Chengjun
    Zhang, Rongyu
    Yang, Chuang
    Wang, Jian
    Yi, Cuihua
    Wang, Xiuwen
    Yu, Shuwen
    Li, Jisheng
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [42] The Importance of Biomarker Testing in the Treatment of Advanced Non-Small Cell Lung Cancer: A Podcast
    Hirsch, Fred R.
    Kim, Chul
    ONCOLOGY AND THERAPY, 2024, 12 (02) : 223 - 231
  • [43] The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
    Fen Wang
    Feng Jin
    Boran Cheng
    Yue Zhang
    Qing Zhou
    Shubin Wang
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 1721 - 1735
  • [44] Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib
    Yao, Zong-Han
    Liao, Wei-Yu
    Ho, Chao-Chi
    Chen, Kuan-Yu
    Shih, Jin-Yuan
    Chen, Jin-Shing
    Lin, Zhong-Zhe
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    Yu, Chong-Jen
    ONCOLOGIST, 2017, 22 (09) : 1075 - 1083
  • [45] Clinical Study of Pemetrexed as the First-line Treatment in Elderly Patients with Advanced Non-squamous Non-small Cell Lung Cancer
    Pu Xiaolin
    Wang Jun
    Li Wei
    Lu Binbin
    Wang Zhaoxia
    Yang Min
    Fan Weifei
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2013, 1 (04): : 205 - 209
  • [46] Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset
    Waterhouse, David
    Lam, Jenny
    Betts, Keith A.
    Yin, Lei
    Gao, Sophie
    Yuan, Yong
    Hartman, John
    Rao, Sumati
    Lubinga, Solomon
    Stenehjem, David
    DATA IN BRIEF, 2021, 37
  • [47] Proposal of real-world solutions for the implementation of predictive biomarker testing in patients with operable non-small cell lung cancer
    Hofman, Paul
    Christopoulos, Petros
    D'Haene, Nicky
    Gosney, John
    Normanno, Nicola
    Schuuring, Ed
    Tsao, Ming-Sound
    Quinn, Christine
    Russell, Jayne
    Keating, Katherine E.
    Lopez-Rios, Fernando
    LUNG CANCER, 2025, 201
  • [48] Real-world ePRO use and clinical outcomes using electronic patient-reported symptom monitoring for patients with advanced non-small-cell lung cancer receiving first-line pembrolizumab
    Blakely, L. Johnetta
    Oskar, Sabine
    Kudel, Ian
    Roush, Ashley
    Shamsi, Zoya
    Perry, Toni
    Christianson, Annette
    Smith, Brittni
    Burke, Thomas
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2025, 14 (02)
  • [49] Treatment Patterns, Clinical Outcomes and Healthcare Costs of Advanced Non-Small Cell Lung Cancer: A Real-World Evaluation in Italy
    Franchi, Matteo
    Cortinovis, Diego
    Corrao, Giovanni
    CANCERS, 2021, 13 (15)
  • [50] Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: recommendations for clinical practice
    De Marinis, Filippo
    Barberis, Massimo
    Barbieri, Vito
    Marchiano, Alfonso
    Gasparini, Stefano
    Migliorino, Maria Rita
    Romano, Giampiero
    Spinnato, Francesca
    Vitiello, Fabiana
    Gridelli, Cesare
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (03) : 217 - 228
12345